Clinical Trial Update: Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease [Phase 2, Phase 3]

View source ↗

Summary

Skyhawk Therapeutics is conducting a Phase 2/3 trial of SKY-0515 in Huntington's disease, currently recruiting to evaluate safety, efficacy, and pharmacodynamic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SKY-0515

Snippet

Sponsor: Skyhawk Therapeutics, Inc. | Conditions: Huntington Disease, Huntingtons Disease | Phase 2, Phase 3 | Status: RECRUITING